Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL NEONATAL JAUNDICE MANAGEMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 MARKETS COVERED
2.3 GEOGRAPHICAL SCOPE
2.4 ARRIVING AT THE GLOBAL NEONATAL JAUNDICE MANAGEMENT MARKET SIZE
2.4.1 VENDOR POSITIONING GRID
2.4.2 MANAGEMENT LIFE LINE CURVE
2.4.3 TRIPOD DATA VALIDATION MODEL
2.4.4 MARKET GUIDE
2.4.5 MULTIVARIATE MODELLING
2.4.6 TOP TO BOTTOM ANALYSIS
2.4.7 CHALLENGE MATRIX
2.4.8 APPLICATION COVERAGE GRID
2.4.9 STANDARDS OF MEASUREMENT
2.4.10 VENDOR SHARE ANALYSIS
2.4.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.4.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.5 GLOBAL NEONATAL JAUNDICE MANAGEMENT MARKET: RESEARCH SNAPSHOT
2.6 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.1.1 RISING PATIENT POPULATION SUFFERING FROM NEONATAL JAUNDICE
3.1.2 LARGE NUMBER OF RISK FACTORS
3.1.3 RISING NUMBER OF NEW-BORN INFANTS
3.1.4 INCREASE IN PRETERM BIRTH
3.1.5 AWARENESS ABOUT NEONATAL JAUNDICE AMONG THE POPULATION
3.2 RESTRAINTS
3.2.1 SIDE-EFFECTS RELATED TO PHOTOTHERAPY
3.2.2 PRODUCT RECALLS
3.2.3 LIMITED ADOPTION OF NEONATAL JAUNDICE MANAGEMENT
3.3 OPPORTUNITIES
3.3.1 INCREASING HEALTHCARE EXPENDITURE
3.3.2 TECHNOLOGICAL ADVANCEMENT IN DIAGNOSIS AND TREATMENT
3.3.3 INCREASING DISPOSABLE INCOME
3.3.4 INCREASE IN AGREEMENTS AND ACQUISITIONS
3.4 CHALLENGES
3.4.1 COMPLICATIONS RELATED TO NEONATAL JAUNDICE
3.4.2 LACK OF SKILLED PROFESSIONALS
3.4.3 DIAGNOSIS OF NEONATAL JAUNDICE
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
6 INDUSTRY INSIGHTS
7 REGULATORY FRAMWORK
8 IMPACT OF COVID-19 PANDEMIC ON THE MARKET
8.1 PRICE IMPACT
8.2 IMPACT ON DEMAND
8.3 IMPACT ON SUPPLY CHAIN
8.4 STRATEGIC DECISION FOR MANUFACTURER/SERVICE PROVIDER
8.5 CONCLUSION
9 GLOBAL NEONATAL JAUNDICE MANAGEMENT MARKET, BY MANAGEMENT
9.1 OVERVIEW
9.2 DIAGNOSIS
9.2.1 TRANSCUTANEOUS BILIRUBINOMETER (TCB)
9.2.2 TOTAL SERUM BILIRUBIN (TSB)
9.2.3 VISUAL ASSESSMENT
9.3 TREATMENT
9.3.1 PHOTOTHERAPY
9.3.1.1. LED PHOTOTHERAPY
9.3.1.2. FIBREOPTIC PHOTOTHERAPY
9.3.1.3. CONVENTIONAL PHOTOTHERAPY
9.3.1.3.1. CONVENTIONAL PHOTOTHERAPY WITH COMPACT FLUORESCENT LAMP
9.3.1.3.2. CONVENTIONAL PHOTOTHERAPY WITH FLUORESCENT LAMP
9.3.1.3.2.1 FULL-BODY PHOTOTHERAPY
9.3.1.3.2.2 PARTIAL-BODY PHOTOTHERAPY
9.3.1.3.3. EXCHANGE TRANSFUSION
9.3.1.3.4. INTRAVENOUS IMMUNOGLOBULIN
9.3.1.3.5. OTHERS
10 GLOBAL NEONATAL JAUNDICE MANAGEMENT MARKET, BY TYPE
10.1 OVERVIEW
10.2 PRIMARY CARE
10.3 SEODNARY CARE
11 GLOBAL NEONATAL JAUNDICE MANAGEMENT MARKET, BY TECHNOLOGY
11.1 OVERVIEW
11.2 FLUORESCENT
11.3 HALOGEN
11.4 FIBEROPTIC
11.5 LIGHT-EMITTING DIODE LIGHT SOURCES
11.6 OTHERS
12 GLOBAL NEONATAL JAUNDICE MANAGEMENT MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITALS
12.3 CLINICS
12.4 AMBULATORY SURGICAL CENTERS
12.5 HOME USERS
12.6 OTHERS
13 GLOBAL NEONATAL JAUNDICE MANAGEMENT MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDERS
13.3 RETAIL SALES
13.4 THIRD PARTY DISTRIBUTION
14 GLOBAL NEONATAL JAUNDICE MANAGEMENT MARKET, BY COUNTRY
14.1 GLOBAL NEONATAL JAUNDICE MANAGEMENT MARKET (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
14.1.1 NORTH AMERICA
14.1.1.1. U.S.
14.1.1.2. CANADA
14.1.1.3. MEXICO
14.1.2 EUROPE
14.1.2.1. GERMANY
14.1.2.2. U.K.
14.1.2.3. FRANCE
14.1.2.4. ITALY
14.1.2.5. SPAIN
14.1.2.6. NETHERLANDS
14.1.2.7. RUSSIA
14.1.2.8. SWITZERLAND
14.1.2.9. TURKEY
14.1.2.10. REST OF EUROPE
14.1.3 ASIA-PACIFIC
14.1.3.1. CHINA
14.1.3.2. JAPAN
14.1.3.3. INDIA
14.1.3.4. AUSTRALIA
14.1.3.5. SOUTH KOREA
14.1.3.6. SINGAPORE
14.1.3.7. MALAYSIA
14.1.3.8. THAILAND
14.1.3.9. INDONESIA
14.1.3.10. PHILIPPINES
14.1.3.11. REST OF ASIA-PACIFIC
14.1.4 SOUTH AMERICA
14.1.4.1. BRAZIL
14.1.4.2. ARGENTINA
14.1.4.3. REST OF SOUTH AMERICA
14.1.5 MIDDLE EAST AND AFRICA
14.1.5.1. SOUTH AFRICA
14.1.5.2. SAUDI ARABIA
14.1.5.3. UAE
14.1.5.4. EGYPT
14.1.5.5. ISRAEL
14.1.5.6. REST OF MIDDLE EAST AND AFRICA
14.1.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
15 GLOBAL NEONATAL JAUNDICE MANAGEMENT MARKET, COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: GLOBAL
15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
15.3 COMPANY SHARE ANALYSIS: EUROPE
15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
15.5 MERGERS & ACQUISITIONS
15.6 NEW PRODUCT DEVELOPMENT & APPROVALS
15.7 EXPANSIONS
15.8 REGULATORY CHANGES
15.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
16 GLOBAL NEONATAL JAUNDICE MANAGEMENT MARKET, SWOT AND DBR ANALYSIS
17 GLOBAL NEONATAL JAUNDICE MANAGEMENT MARKET, COMPANY PROFILE
17.1 DRÄGERWERK AG & CO. KGAA,
17.1.1 COMPANY OVERVIEW
17.1.2 REVENUE ANALYSIS
17.1.3 GEOGRAPHIC PRESENCE
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENTS
17.2 ATOM MEDICAL CORP
17.2.1 COMPANY OVERVIEW
17.2.2 REVENUE ANALYSIS
17.2.3 GEOGRAPHIC PRESENCE
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENTS
17.3 MTTS
17.3.1 COMPANY OVERVIEW
17.3.2 REVENUE ANALYSIS
17.3.3 GEOGRAPHIC PRESENCE
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENTS
17.4 PHOENIX MEDICAL SYSTEMS PVT. LTD
17.4.1 COMPANY OVERVIEW
17.4.2 REVENUE ANALYSIS
17.4.3 GEOGRAPHIC PRESENCE
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENTS
17.5 AVIHEALTHCARE
17.5.1 COMPANY OVERVIEW
17.5.2 REVENUE ANALYSIS
17.5.3 GEOGRAPHIC PRESENCE
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENTS
17.6 IBIS MEDICAL
17.6.1 COMPANY OVERVIEW
17.6.2 REVENUE ANALYSIS
17.6.3 GEOGRAPHIC PRESENCE
17.6.4 PRODUCT PORTFOLIO
17.6.5 RECENT DEVELOPMENTS
17.7 NATUS MEDICAL INCORPORATED
17.7.1 COMPANY OVERVIEW
17.7.2 REVENUE ANALYSIS
17.7.3 GEOGRAPHIC PRESENCE
17.7.4 PRODUCT PORTFOLIO
17.7.5 RECENT DEVELOPMENTS
17.8 NINGBO DAVID MEDICAL DEVICE CO., LTD
17.8.1 COMPANY OVERVIEW
17.8.2 REVENUE ANALYSIS
17.8.3 GEOGRAPHIC PRESENCE
17.8.4 PRODUCT PORTFOLIO
17.8.5 RECENT DEVELOPMENTS
17.9 WEYER GMBH
17.9.1 COMPANY OVERVIEW
17.9.2 REVENUE ANALYSIS
17.9.3 GEOGRAPHIC PRESENCE
17.9.4 PRODUCT PORTFOLIO
17.9.5 RECENT DEVELOPMENTS
17.1 SOLARC SYSTEMS INC.,
17.10.1 COMPANY OVERVIEW
17.10.2 REVENUE ANALYSIS
17.10.3 GEOGRAPHIC PRESENCE
17.10.4 PRODUCT PORTFOLIO
17.10.5 RECENT DEVELOPMENTS
17.11 GE HEALTHCARE
17.11.1 COMPANY OVERVIEW
17.11.2 REVENUE ANALYSIS
17.11.3 GEOGRAPHIC PRESENCE
17.11.4 PRODUCT PORTFOLIO
17.11.5 RECENT DEVELOPMENTS
17.12 PHILIPS LIGHTING HOLDING B.V.
17.12.1 COMPANY OVERVIEW
17.12.2 REVENUE ANALYSIS
17.12.3 GEOGRAPHIC PRESENCE
17.12.4 PRODUCT PORTFOLIO
17.12.5 RECENT DEVELOPMENTS
17.13 IHR. LTD.
17.13.1 COMPANY OVERVIEW
17.13.2 REVENUE ANALYSIS
17.13.3 GEOGRAPHIC PRESENCE
17.13.4 PRODUCT PORTFOLIO
17.13.5 RECENT DEVELOPMENTS
17.14 ZHENGZHOU DISON INSTRUMENT AND METER CO., LTD
17.14.1 COMPANY OVERVIEW
17.14.2 REVENUE ANALYSIS
17.14.3 GEOGRAPHIC PRESENCE
17.14.4 PRODUCT PORTFOLIO
17.14.5 RECENT DEVELOPMENTS
17.15 HERBERT WALDMANN GMBH & CO. KG
17.15.1 COMPANY OVERVIEW
17.15.2 REVENUE ANALYSIS
17.15.3 GEOGRAPHIC PRESENCE
17.15.4 PRODUCT PORTFOLIO
17.15.5 RECENT DEVELOPMENTS
17.16 NICE NEOTECH MEDICAL SYSTEMS PVT. LTD.
17.16.1 COMPANY OVERVIEW
17.16.2 REVENUE ANALYSIS
17.16.3 GEOGRAPHIC PRESENCE
17.16.4 PRODUCT PORTFOLIO
17.16.5 RECENT DEVELOPMENTS
17.17 GINEVRI SRL
17.17.1 COMPANY OVERVIEW
17.17.2 REVENUE ANALYSIS
17.17.3 GEOGRAPHIC PRESENCE
17.17.4 PRODUCT PORTFOLIO
17.17.5 RECENT DEVELOPMENTS
17.18 NEOLIGHT LLC
17.18.1 COMPANY OVERVIEW
17.18.2 REVENUE ANALYSIS
17.18.3 GEOGRAPHIC PRESENCE
17.18.4 PRODUCT PORTFOLIO
17.18.5 RECENT DEVELOPMENTS
17.19 S S TECHNOMED (P) LTD
17.19.1 COMPANY OVERVIEW
17.19.2 REVENUE ANALYSIS
17.19.3 GEOGRAPHIC PRESENCE
17.19.4 PRODUCT PORTFOLIO
17.19.5 RECENT DEVELOPMENTS
17.2 SHVABE‑ZURICH GMBH
17.20.1 COMPANY OVERVIEW
17.20.2 REVENUE ANALYSIS
17.20.3 GEOGRAPHIC PRESENCE
17.20.4 PRODUCT PORTFOLIO
17.20.5 RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST RELATED REPORTS
18 CONCLUSION
19 QUESTIONNAIRE
20 ABOUT DATA BRIDGE MARKET RESEARCH
